Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • Breakthrough Discoveries
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Jiemiao Hu Image

      Jiemiao Hu, Ph.D.

      Department of Pediatrics, Division of Pediatrics

      Present Title & Affiliation

      Dual/Joint/Adjunct Appointment

      Assistant Professor, Department of Pediatrics – Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2013University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, US, Ph.D. in Biomedical Sciences
      2007Peking Union Medical College, Beijing, CN, M.S. in Biochemistry and Molecular Biology
      2004Peking University, Beijing, CN, BS in Chemistry

      Postgraduate Training

      2013-2018Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Experience & Service

      Faculty Academic Appointments

      Instructor, Department of Pediatrics – Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2018 - 2021

      Intramural Institutional Committee Activities

      reviewer, Odyssey Program Advisory Committee, The University of Texas MD Anderson Cancer Center, 2026 - Present

      Editorial Activities

      Editorial Board member, Frontiers in Immunology, 2024 - Present

      Honors & Awards

      2018Scholarship, Keystone Symposia Conference Cancer Immunotherapy (C5)
      2012 - PresentTravel Award
      2011 - PresentTravel Award, University of Texas Graduate School of the Biomedical Sciences
      2006 - 2007Merit student, Peking Union Medical College

      Professional Memberships

      Connective Tissue Oncology Society

      2026 - Present

      American Association of Immunologists

      2016 - Present

      American Association of Cancer Research

      2010 - Present

      Selected Presentations & Talks

      National Presentations

      1. 2026. Evaluate the feasibility and enhanced activity of attIL12-engineered chordoma specific T cells. Invited. Joint Tri-SPORE Translational Science Seminar Series 2026.
      2. 2022. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. Conference. 105th American Association of Immunologists annual meeting IMMUNOLOGY2022. Portland, OR, US.
      3. 2020. CRS free T cell therapy: T cell membrane anchored and tumor targeted IL12 (ATTIL12)-T cell therapy eliminates large tumors, overcomes heterogeneity, and avoids adverse effects. Conference. IMMUNOLOGY2020. Honolulu, HI, US.
      4. 2016. CXCL9, CXCL10 and IFNγ favor the accumulation of infused T cells in tumors following IL-12 plus doxorubicin treatment. Conference. 100th American Association of Immunologists annual meeting IMMUNOLOGY2016. Seattle, WA, US.

      International Presentations

      1. 2026. Collagen-disrupting attIL12 TIL therapy boosts deep T-cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Invited. CTOS 2026. Seoul, KR.
      2. 2018. Combinational Therapy for Boosting T Cell Transfer to Overcome Heterogeneity and Immune Suppression of Solid Tumors. Conference. Keystone Symposia Cancer Immunotherapy (C5). Montreal, CA.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - Present
      Title:CCKAR-CAR-γδT Cell Transfer for Improving Osteosarcoma Treatment via Extracellular Matrix Disruption
      Funding Source:United States Department of Defense
      Role:PI
      ID:FP00032206
      Date: 2025 - 2030
      Title:MD Anderson Sarcoma SPORE
      Funding Source:NIH SPORE
      Role:Co-I
      Date: 2025 - 2028
      Title:Novel Therapies for Osteosarcoma
      Funding Source:CPRIT MIRA
      Role:Co-I

      Selected Publications

      Peer-Reviewed Articles

      1. Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R, Li S. Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Proc Natl Acad Sci U S A 122(41):e2507542122, 2025. e-Pub 2025. PMID: 41052334.
      2. Hu, J, Lazar, A, Ingram, D, Wang, W, Zhang, W, Jia, Z, Ragoonanan, D, Wang, J, Xia, X, Mahadeo, KM, Gorlick, R, Li, S. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models. J Immunother Cancer 12(1), 2024. e-Pub 2024. PMID: 38199607.
      3. Zhao Q, Hu J, Kong L, Jiang S, Tian X, Wang J, Hashizume R, Jia Z, Fowlkes NW, Yan J, Xia X, Yi SF, Dao LH, Masopust D, Heimberger AB, Li S. FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nat Commun 14(1):735, 2023. e-Pub 2023. PMID: 36759517.
      4. Dao L, Zhao Q, Hu J, Xia X, Yang Q, Li S. A microfluidics-based method for isolation and visualization of cells based on receptor-ligand interactions. PLoS One 17(10):e0274601, 2022. e-Pub 2022. PMID: 36201506.
      5. Yang Q*, Hu J*, Jia Z, Wang Q, Wang J, Dao LH, Zhang W, Zhang S, Xia X, Gorlick R, Li S. Membrane-anchored and tumor-targeted IL-12 (attIL12)-PBMC therapy for osteosarcoma. Clin Cancer Res 28(17):3862-3873, 2022. e-Pub 2022. PMID: 35727602.
      6. Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, Dao L, Xia X, Wall FN, Zhang Z, Mahadeo KM, Gorlick R, Kopetz S, Dotti G, Li S. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J Immunother Cancer 10(1), 2022. e-Pub 2022. PMID: 35027427.
      7. Wu M, Xia X, Hu J, Fowlkes NW, Li S. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. Nat Commun 12(1):3500, 2021. e-Pub 2021. PMID: 34108491.
      8. Hu J, Xia X, Zhao Q, Li S. Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance. Cancer Lett 502:143-153, 2021. e-Pub 2021. PMID: 33279621.
      9. Hu J, Zhao Q, Kong LY, Wang J, Yan J, Xia X, Jia Z, Heimberger AB, Li S. Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv 7(5), 2021. e-Pub 2021. PMID: 33571109.
      10. Hu J, Xia X, Gorlick R, Li S. Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor. Oncogene 38(49):7433-7446, 2019. e-Pub 2019. PMID: 31427736.
      11. Zhao Q*, Hu J*, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J Immunother Cancer 7(1):154, 2019. e-Pub 2019. PMID: 31208461.
      12. Hu J, Sun C, Bernatchez C, Xia X, Hwu P, Dotti G, Li S. T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors. Clin Cancer Res 24(12):2920-2934, 2018. e-Pub 2018. PMID: 29391351.
      13. Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunol Res 5(4):300-311, 2017. e-Pub 2017. PMID: 28223282.
      14. Hu J, Batth IS, Xia X, Li S. Regulation of NKG2D+CD8+ T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism. Oncoimmunology 5(12):e1252012, 2016. e-Pub 2016. PMID: 28123894.
      15. Satelli A, Hu J, Xia X, Li S. Potential Function of Exogenous Vimentin on the Activation of Wnt Signaling Pathway in Cancer Cells. J Cancer 7(13):1824-1832, 2016. e-Pub 2016. PMID: 27698922.
      16. Yan J, Mitra A, Hu J, Cutrera JJ, Xia X, Doetschman T, Gagea M, Mishra L, Li S. Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. J Hepatol 64(5):1128-1136, 2016. e-Pub 2016. PMID: 26767500.
      17. Yan J, Kong LY, Hu J, Gabrusiewicz KR, Dibra D, Xia X, Heimberger AB, Li S. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. J Natl Cancer Inst 107(8), 2015. e-Pub 2015. PMID: 25971300.
      18. Noh H*, Hu J*, Wang X*, Xia X, Satelli A, Li S. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal 13(1):14, 2015. e-Pub 2015. PMID: 25889536.
      19. Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Mol Cancer 13(1):34, 2014. e-Pub 2014. PMID: 24565056.
      20. Hu J, Vien LT, Xia X, Bover L, Li S. Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells. Biol Proced Online 16(1):3, 2014. e-Pub 2014. PMID: 24495546.
      21. Flanagan, M, Gimble, JM, Yu, G, Wu, X, Xia, X, Hu, J, Yao, S, Li, S. Competitive electroporation formulation for cell therapy. Cancer Gene Ther 18(8):579-586, 2011. e-Pub 2011. PMID: 21660061.
      22. Hu J, Liu X, Hughes D, Esteva FJ, Liu B, Chandra J, Li S. Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis. PLoS One 6(8):e23270, 2011. e-Pub 2011. PMID: 21853100.
      23. Liu D, Yuan G, Hu J. Synthesis and photo-induced DNA cleaving activities of conjugates of halophenyl derivative and polyamide containing N-methylimidazoles. J Photochem Photobiol B 83(3):187-193, 2006. e-Pub 2006. PMID: 16403643.

      Invited Articles

      1. Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol 35(4):325-339, 2016. e-Pub 2016. PMID: 25259408.

      Other Articles

      1. Hu J, Liu X, Huang Q, Zhang B, Hughes D, Chandra J, Xia X, Li S Herceptin trimers linked by EDC could boost direct tumor cell death and overcome resistance to trastuzumab treatment via programmed tumor cell necrosis. 102nd Annual Meeting of the American Association for Cancer Research, 2011.

      Abstracts

      1. Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R, Li S. Novel mechanism for eliminating tumor collagens to boost efficacy by attIL12-TIL therapy in PDX sarcoma models. 117th American Association of Cancer Research, 2026. e-Pub 2026.
      2. Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R, Li S. Collagen-disrupting attIL12 TIL therapy boosts deep T-cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. 108th American Association of Immunologists (AAI) IMMUNOLOGY, 2025.
      3. Livingston J, Ragoonanan D, Tewari P, Gill JB, Banck S, Gao M, Lin HY, Li Y, Xia X, Hu J, Jin Y, Shpall EJ, Kaur I, Asfaw T, Alvarez F, Wang W, Somaiah N, Patel S, Gorlick RG, Li S. A first-in-human phase 1 trial of T cell membrane-anchored tumor targeted IL12 (ATTIL12) -T cell therapy in advanced/metastatic soft tissue and bone sarcoma. American Society of Clinical Oncology 42(16_suppl), 2024. e-Pub 2024.
      4. Hu J, Lazar A, Ingram D, Wang W, Zhang W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, Gorlick R, Li S. attIL12-T cell therapy destructs cancer-associated fibroblasts and extracellular matrix in heterogenous osteosarcoma xenograft models. 114th American Association for Cancer Research Annual Meeting 2023 83((7_Supplement): 4102), 2023. e-Pub 2023.
      5. Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, Dao L, Xia X, Wall FN, Zhang Z, Mahadeo K, Gorlick R, Kopetz S, Dotti G, Li S. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. 105th American Association of Immunologists, IMMUNOLOGY 2022 J Immunol (2022) 208 (1_Supplement): 117.13, 2022.
      6. Hu J. CRS free T cell therapy: T cell membrane anchored and tumor targeted IL12 (ATTIL12)-T cell therapy eliminates large tumors, overcomes heterogeneity, and avoids adverse effects. 104th American Association of Immunologists (AAI), IMMUNOLOGY 2020 Accepted, 2020.
      7. Hu J, Xia X, Li S. Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor. 110th American Association for Cancer Research Annual Meeting 2019 Cancer Res (2019) 79 (13_Supplement): 1196, 2019.
      8. Hu J. Combinational Therapy for Boosting T Cell Transfer to Overcome Heterogeneity and Immune Suppression of Solid Tumors. Cancer Immunotherapy: Combinations (C5) 2018, Keystone Symposia, 2018.
      9. Hu J, Batth I, Bernatchez C, Xia X, Hwu P, Gorlick R, Li S. NKG2D ligand–inducing immune therapy plus NKG2D+CD8+ T cell therapy overcomes chemoresistance in tumors. Society for Immunotherapy of Cancer 2017 Annual Meeting P179, 2017.
      10. Hu J, Bernatchez C, Xia X, Xu Z, Hwu P, Li S. CXCL9, CXCL10 and IFNγ favor the accumulation of infused T cells in tumors following IL-12 plus doxorubicin treatment. 100th American Association of Immunologists, IMMUNOLOGY 2016 J Immunol (2016) 196 (1_Supplement): 212.1, 2016.
      11. Hu J, Xia X, Kleinerman ES, Li S. CD8+T cell-mediated tumor-specific induction of the NKG2D ligands to trigger NKG2D-dependent tumor cell death in vivo. 106th American Association for Cancer Research Annual Meeting 75(15_Supplement):4047, 2015. e-Pub 2015.
      12. Hu J, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 requires the engagement of CD80 and CD28. 105th Annual Meeting of the American Association for Cancer Research Cancer Res (2014) 74 (19_Supplement): 160, 2014.
      13. Hu J, Zhu S, Kleinerman E, Li S. Co-stimulation of IL-12 gene delivery plus doxorubicin induces NKG2D-dependent CD8+T cell infiltration to tumors and inhibition of tumor progression. 104th Annual Meeting of the American Association for Cancer Research 2013 Cancer Res (2013) 73 (8_Supplement): 4996, 2013.
      14. Hu J, Zhu S, Xia X, Yokoyama WM, Li S. Regulation of NKG2D expression and NKG2D-positive T cell tumor-specific trafficking by doxorubicin and IL-12 in vivo. 103rd Annual Meeting of the American Association for Cancer Research Cancer Res (2012) 72 (8_Supplement): 404, 2012.
      15. Hu J. Collagen-disrupting ATTIL12 TIL therapy boosts deep T-cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Connective Tissue Oncology Society (CTOS) Foudational Science of Sarcomas Symposium Seoul, Korea.

      Book Chapters

      1. Hu J, Li S. Electroporation formulation for cell therapy. In: Methods Mol Biol, 55-60, 2014.
      2. Hu J, Cutrera J, Li S. The impact of non-electrical factors on electrical gene transfer. In: Methods Mol Biol, 47-54, 2014.

      Patents

      1. FGL2 monoclonal antibodies and their use in treating malignant tumors. Patent Number: 11512141.
      2. Shulin Li, Jiemiao Hu, Xueqing Xia. T Cells Expressing Membrane-Anchored IL-12 for the Treatment of Cancer. Patent Number: 1142010.
      3. Hu J. FGL2 Monoclonal Antibodies And Their Use In Treating Malignant Tumors. Patent Number: CN110831622B.
      Read More
      Less

      Patient Reviews


      CV information above last modified November 19, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top